Business
Company Share Purchases by Directors
Company Share Purchases by Directors.
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n \n \n \n \n \n 20 July 2022\n \n \n \n \n \n \n \n \n Genflow Biosciences Plc\n \n \n \n \n \n \n \n \n (\"Genflow\" or \"the Company\")\n \n \n \n \n \n \n Company Share Purchases by Directors\n \n \n \n Genflow Biosciences (LSE: GENF)\n , a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age,\n \n \n announces that it was notified on 18 July 2022 that Yassine Bendiabdallah, Chairman of the Company, and Peter King-Lewis, a non-executive director of the Company, each purchased the following Ordinary Shares:\n \n \n \n \n \n \n \n \n \n \n PDMR / Person closely associated\n \n \n \n \n \n \n Total Number of Ordinary Shares Purchased\n \n \n \n \n \n \n Weighted Average Price per Ordinary Share\n \n \n \n \n \n \n Resultant Shareholding\n \n \n \n \n \n \n Percentage Of The Total Voting Rights of the Company\n \n \n \n \n \n \n \n Yassine Bendiabdallah\n \n \n \n \n 108,000\n \n \n \n \n 0.037\n \n \n \n \n 470,500\n \n \n \n \n 0.16\n \n \n \n \n \n \n Peter King-Lewis\n \n \n \n \n 82,000\n \n \n \n \n 0.037\n \n \n \n \n 382,000\n \n \n \n \n 0.13\n \n \n \n \n \n \n \n \n \n Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link:\n \n \n \n https://genflowbio.com/investors/news-releases/\n \n \n \n The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.\n \n \n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n \n \n \n Genflow Biosciences\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Dr Eric Leire\n \n \n \n Chief Executive\n \n \n \n \n via Tancredi +44 203 434 2330\n \n \n \n \n \n \n \n Clear Capital\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Corporate Broker \n \n \n \n \n \n Jonathan Critchley\n \n \n Keith Swann\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n +44 203 869 6086\n \n \n \n \n \n +44 203 897 0981\n \n \n \n \n \n \n \n Tancredi Intelligent Communication\n \n \n \n Media Relations\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Salamander Davoudi\n \n \n \n \n Helen Humphrey\n \n \n \n \n Benedetta Negri ...